Background: Alzheimer’s disease (AD) is a neurodegenerative disorder where β-amyloid tends to aggregate and form plaques. Lipid raft-associated ganglioside GM1 has been suggested to facilitate β-amyloid aggregation; furthermore, GM1 and GM2 are increased in lipid rafts isolated from cerebral cortex of AD cases. Aim/Method: The distribution of GM1 and GM2 was studied by immunohistochemistry in the frontal and temporal cortex of AD cases. Frontotemporal dementia (FTD) was included as a contrast group. Results: The distribution of GM1 and GM2 changes during the process of AD (n = 5) and FTD (n = 3) compared to controls (n = 5). Altered location of the GM1-positive small circular structures seems to be associated with myelin degradation. In the grey matter, the staining of GM1-positive plasma membranes might reflect neuronal loss in the AD/FTD tissue. The GM1-positive compact bundles were only visible in cells located in the AD frontal grey matter, possibly reflecting raft formation of GM1 and thus a pathological connection. Furthermore, our results suggest GM2 to be enriched within vesicles of pyramidal neurons of the AD/FTD brain. Conclusion: Our study supports the biochemical finding of ganglioside accumulation in cellular membranes of AD patients and shows a redistribution of these molecules.

1.
Blennow K, de Leon MJ, Zetterberg H: Alzheimer’s disease. Lancet 2006;368:387–403.
2.
Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
3.
Selkoe DJ: Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 1994;17:489–517.
4.
Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Harigaya Y: Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol 1988;77:113–119.
5.
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985;82:4245–4249.
6.
Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A: Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 1988;85:4051–4055.
7.
Kosik KS: Tau protein and neurodegeneration. Mol Neurobiol 1990;4:171–179.
8.
Katzman R, Saitoh T: Advances in Alzheimer’s disease. FASEB J 1991;5:278–286.
9.
Selkoe DJ: The molecular pathology of Alzheimer’s disease. Neuron 1991;6:487–498.
10.
Wallin AK, Blennow K, Andreasen N, Minthon L: CSF biomarkers for Alzheimer’s disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 2006;21:131–138.
11.
Snowden JS, Neary D, Mann DM: Frontotemporal dementia. Br J Psychiatry 2002;180:140–143.
12.
Simons K, Ikonen E: Functional rafts in cell membranes. Nature 1997;387:569–572.
13.
Brown DA, London E: Structure and origin of ordered lipid domains in biological membranes. J Membr Biol 1998;164:103–114.
14.
Hooper NM: Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae (review). Mol Membr Biol 1999;16:145–156.
15.
Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science 2010;327:46–50.
16.
Laude AJ, Prior IA: Plasma membrane microdomains: organization, function and trafficking. Mol Membr Biol 2004;21:193–205.
17.
Rajendran L, Simons K: Lipid rafts and membrane dynamics. J Cell Sci 2005;118:1099–1102.
18.
Hanzal-Bayer MF, Hancock JF: Lipid rafts and membrane traffic. FEBS Lett 2007;581:2098–2104.
19.
Ehehalt R, Keller P, Haass C, Thiele C, Simons K: Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003;160:113–123.
20.
Cordy JM, Hooper NM, Turner AJ: The involvement of lipid rafts in Alzheimer’s disease. Mol Membr Biol 2006;23:111–122.
21.
Vetrivel KS, Thinakaran G: Membrane rafts in Alzheimer’s disease beta-amyloid production. Biochim Biophys Acta 2010;1801:860–867.
22.
Eckert GP, Cairns NJ, Maras A, Gattaz WF, Muller WE: Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer’s disease. Dement Geriatr Cogn Disord 2000;11:181–186.
23.
Riddell DR, Christie G, Hussain I, Dingwall C: Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol 2001;11:1288–1293.
24.
Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE: Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 2002;9:11–23.
25.
Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ: Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2003;100:11735–11740.
26.
Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, Wong PC, Xu H, Thinakaran G: Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J Biol Chem 2004;279:44945–44954.
27.
Urano Y, Hayashi I, Isoo N, Reid PC, Shibasaki Y, Noguchi N, Tomita T, Iwatsubo T, Hamakubo T, Kodama T: Association of active gamma-secretase complex with lipid rafts. J Lipid Res 2005;46:904–912.
28.
Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT Jr, Kosik KS: A detergent-insoluble membrane compartment contains A beta in vivo. Nat Med 1998;4:730–734.
29.
Michel V, Bakovic M: Lipid rafts in health and disease. Biol Cell 2007;99:129–140.
30.
Yanagisawa K, Odaka A, Suzuki N, Ihara Y: GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer’s disease. Nat Med 1995;1:1062–1066.
31.
Choo-Smith LP, Surewicz WK: The interaction between Alzheimer amyloid beta(1–40) peptide and ganglioside GM1-containing membranes. FEBS Lett 1997;402:95–98.
32.
McLaurin J, Franklin T, Fraser PE, Chakrabartty A: Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides. J Biol Chem 1998;273:4506–4515.
33.
Matsuzaki K, Horikiri C: Interactions of amyloid beta-peptide (1–40) with ganglioside-containing membranes. Biochemistry 1999;38:4137–4142.
34.
Ariga T, Kobayashi K, Hasegawa A, Kiso M, Ishida H, Miyatake T: Characterization of high-affinity binding between gangliosides and amyloid beta-protein. Arch Biochem Biophys 2001;388:225–230.
35.
Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K: Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 2002;41:7385–7390.
36.
Zha Q, Ruan Y, Hartmann T, Beyreuther K, Zhang D: GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol Psychiatry 2004;9:946–952.
37.
Utsumi M, Yamaguchi Y, Sasakawa H, Yamamoto N, Yanagisawa K, Kato K: Up-and-down topological mode of amyloid beta-peptide lying on hydrophilic/hydrophobic interface of ganglioside clusters. Glycoconj J 2009;26:999–1006.
38.
Svennerholm L, Bostrom K, Fredman P, Mansson JE, Rosengren B, Rynmark BM: Human brain gangliosides: developmental changes from early fetal stage to advanced age. Biochim Biophys Acta 1989;1005:109–117.
39.
Ledeen RW, Cochran FB, Yu RK, Samuels FG, Haley JE: Gangliosides of the CNS myelin membrane. Adv Exp Med Biol 1980;125:167–176.
40.
Iwamoto N, Suzuki Y, Makino Y, Haga C, Kosaka K, Iizuka R: Cell membrane changes in brains manifesting senile plaques: an immunohistochemical study of GM1 membranous ganglioside. Brain Res 1990;522:152–156.
41.
Kotani M, Kawashima I, Ozawa H, Terashima T, Tai T: Differential distribution of major gangliosides in rat central nervous system detected by specific monoclonal antibodies. Glycobiology 1993;3:137–146.
42.
Molander M, Berthold CH, Persson H, Andersson K, Fredman P: Monosialoganglioside (GM1) immunofluorescence in rat spinal roots studied with a monoclonal antibody. J Neurocytol 1997;26:101–111.
43.
Marconi S, De Toni L, Lovato L, Tedeschi E, Gaetti L, Acler M, Bonetti B: Expression of gangliosides on glial and neuronal cells in normal and pathological adult human brain. J Neuroimmunol 2005;170:115–121.
44.
Fuxe K, Tinner B, Janson AM, Cintra A, Staines W, Agnati LF: On the cellular localization and distribution of the ganglioside GM1 in the rat brain as revealed by immunofluorescence histochemistry of cholera toxin binding sites. Acta Physiol Scand 1989;137:551–552.
45.
Taniguchi M, Shinoda Y, Ninomiya H, Vanier MT, Ohno K: Sites and temporal changes of gangliosides GM1/GM2 storage in the Niemann-Pick disease type C mouse brain. Brain Dev 2001;23:414–421.
46.
Yanagisawa K: GM1 ganglioside and the seeding of amyloid in Alzheimer’s disease: endogenous seed for Alzheimer amyloid. Neuroscientist 2005;11:250–260.
47.
Yamamoto N, Fukata Y, Fukata M, Yanagisawa K: GM1-ganglioside-induced Abeta assembly on synaptic membranes of cultured neurons. Biochim Biophys Acta 2007;1768:1128–1137.
48.
Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K: Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 2001;276:24985–24990.
49.
Matsuzaki K, Kato K, Yanagisawa K: Abeta polymerization through interaction with membrane gangliosides. Biochim Biophys Acta 2010;1801:868–877.
50.
Yamamoto N, Matsubara T, Sato T, Yanagisawa K: Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid beta-protein fibrillogenesis. Biochim Biophys Acta 2008;1778:2717–2726.
51.
Ariga T, McDonald MP, Yu RK: Role of ganglioside metabolism in the pathogenesis of Alzheimer’s disease – a review. J Lipid Res 2008;49:1157–1175.
52.
Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Mansson JE, Fredman P: Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 2005;92:171–182.
53.
Gylys KH, Fein JA, Yang F, Miller CA, Cole GM: Increased cholesterol in Abeta-positive nerve terminals from Alzheimer’s disease cortex. Neurobiol Aging 2007;28:8–17.
54.
Blennow K, Davidsson P, Wallin A, Fredman P, Gottfries CG, Karlsson I, Mansson JE, Svennerholm L: Gangliosides in cerebrospinal fluid in ‘probable Alzheimer’s disease’. Arch Neurol 1991;48:1032–1035.
55.
Yamamoto N, Igbabvoa U, Shimada Y, Ohno-Iwashita Y, Kobayashi M, Wood WG, Fujita SC, Yanagisawa K: Accelerated Abeta aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett 2004;569:135–139.
56.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
57.
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II: Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479–486.
58.
Bogdanovic N, Morris JH: Diagnostic criteria for Alzheimer’s disease in multicenter brain banking; in Cruz-Sanches FF, Ravid R, Cuzner ML (eds): Neuropathological Diagnostic Criteria for Brain Banking. Amsterdam, IOS Press, 1995, pp 20–29.
59.
Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B: Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol 1987;74:209–225.
60.
Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–1554.
61.
Snowden J, Neary D, Mann D: Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol 2007;114:31–38.
62.
Mackenzie IR, Baborie A, Pickering-Brown S, Du Plessis D, Jaros E, Perry RH, Neary D, Snowden JS, Mann DM: Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol 2006;112:539–549.
63.
Karlsson G, Månsson JE, Wikstrand C, Bigner D, Svennerholm L: Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2. Biochim Biophys Acta 1990;1043:267–272.
64.
Cammer W, Zhang H: Atypical glial cells in demyelinated and hypomyelinated mouse brains. Brain Res 1999;837:188–192.
65.
Pernber Z, Molander-Melin M, Berthold CH, Hansson E, Fredman P: Expression of the myelin and oligodendrocyte progenitor marker sulfatide in neurons and astrocytes of adult rat brain. J Neurosci Res 2002;69:86–93.
66.
Fredman P, Mattsson L, Andersson K, Davidsson P, Ishizuka I, Jeansson S, Mansson JE, Svennerholm L: Characterization of the binding epitope of a monoclonal antibody to sulphatide. Biochem J 1988;251:17–22.
67.
Horie K, Miyata T, Yasuda T, Takeda A, Yasuda Y, Maeda K, Sobue G, Kurokawa K: Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer’s disease and aged neurons. Biochem Biophys Res Commun 1997;236:327–332.
68.
Keller JN: Age-related neuropathology, cognitive decline, and Alzheimer’s disease. Ageing Res Rev 2006;5:1–13.
69.
Peters A: The effects of normal aging on myelin and nerve fibers: a review. J Neurocytol 2002;31:581–593.
70.
Persson H, Berthold CH: Cellular relationships of paranodal Marchi-positive bodies studied with monoclonal antibodies against partially degraded CNS myelin fragments. J Neurocytol 1991;20:277–289.
71.
Anderson ES, Bjartmar C, Hildebrand C: Myelination of prospective large fibres in chicken ventral funiculus. J Neurocytol 2000;29:755–764.
72.
van Echten G, Sandhoff K: Ganglioside metabolism: enzymology, topology, and regulation. J Biol Chem 1993;268:5341–5344.
73.
Kimura N, Yanagisawa K: Endosomal accumulation of GM1 ganglioside-bound amyloid beta-protein in neurons of aged monkey brains. Neuroreport 2007;18:1669–1673.
74.
Yuyama K, Yanagisawa K: Late endocytic dysfunction as a putative cause of amyloid fibril formation in Alzheimer’s disease. J Neurochem 2009;109:1250–1260.
75.
Walkley SU, Suzuki K: Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta 2004;1685:48–62.
76.
Molander M, Berthold CH, Persson H, Fredman P: Immunostaining of ganglioside GD1b, GD3 and GM1 in rat cerebellum: cellular layer and cell type specific associations. J Neurosci Res 2000;60:531–542.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.